This article was originally published in The Tan Sheet
Consumer Healthcare sales grew 2% in 2005 to reach $5.46 bil. for the year, GlaxoSmithKline announces Feb. 8. OTC drug sales were up 1% to $2.4 bil. (£ = $1.74), with growth in analgesics up 5% and respiratory tract drugs up 6%. The consumer division's September sale of five U.S. prescription dermatologicals contributed to a 12% drop in sales for the unit. The firm is "absolutely confident" that its Consumer division can continue to increase operating margins, CEO J.P. Garnier stated during an earnings call. The comment was a response to a question about whether the division's operating margins, which have increased from 20% to 24% in recent years, are sustainable. "I think what's going to affect margin is the overall revenue growth of the consumer business in '06," Garnier stated. "But we do have a number of programs where actually we convert cost saving from manufacturing and SG&A into more promotion because promotion drives the sales line in this business." The firm is awaiting an FDA decision on the proposed OTC sale of Alli (orlistat 60 mg)...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."